SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new development or finding in product specification without further noticed.
Chemical Name: (1R,2S)-1-[(3,4-Dimethoxyphenyl)methyl]-2-[3-[[5-[[3-[(1R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]propanoyl]oxy]pentyl]oxy]-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium benzenesulfonate (as per EP)
Synonym: Atracurium EP Impurity A1
Shipping Temperature: Ambient
HSN Code: 38229010
Country of Origin: India
Smiles: O=S(C1=CC=CC=C1)([O-])=O.C[N@+]2(CCC(OCCCCCOC(CCN3[C@H](CC4=CC=C(OC)C(OC)=C4)C5=C(C=C(OC)C(OC)=C5)CC3)=O)=O)[C@H](CC6=CC=C(OC)C(OC)=C6)C7=C(C=C(OC)C(OC)=C7)CC2
Cisatracurium Besylate EP Impurity P is chemically (1R,2S)-1-[(3,4-Dimethoxyphenyl)methyl]-2-[3-[[5-[[3-[(1R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]propanoyl]oxy]pentyl]oxy]-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium benzenesulfonate (as per EP). It is also known as Atracurium EP Impurity A1. Cisatracurium Besylate EP Impurity P is supplied with detailed characterization data compliant with regulatory guideline. Cisatracurium Besylate EP Impurity P can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Cisatracurium.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
HPLC determination of cisatracurium besylate and propofol mixtures with LC-MS identification of degradation products
By Zhang H; Wang P; Bartlett M G; Stewart J T
From Journal of pharmaceutical and biomedical analysis (1998), 16(7), 1241-9